The Global Carrier Screening Market Key Analysis by the year of 2030

As a result of the testing kits becoming more advanced and cost-effective, the global carrier screening market, which reached $1,303.6 million in 2019, is predicted to grow at a 10.9% CAGR between 2020 and 2030. This is because of the increasing efficiency and reducing costs of the tests, which is driving the demand for them, among people planning a family.



Until 2030, the expanded carrier screening split is expected to hold a higher part of the carrier screening market. This is due to the fact that a number of genetic illnesses can be tested for at the same time using this method. Another factor contributing to this bifurcation's dominance in the market is the widespread use of the next-generation sequencing (NGS) technology for genetic disease screening.

Because of the integration of user-friendly tools with the technology and its dropping pricing, the deoxyribonucleic acid (DNA) sequencing division supplied the most revenue to the carrier screening industry in 2019. Furthermore, because those who use it for testing do not need to be bioinformatics experts, this technology is more accessible.

The cystic fibrosis classification would have the greatest CAGR in the carrier screening market during the projection period, owing to the rising number of persons diagnosed with this genetic disorder in North America and Europe. Furthermore, as people become more aware of the benefits of early diagnosis, the number of tests performed is increasing.

Invitae Corporation, Illumina Inc., Thermo Fisher Scientific Inc., Otogenetics Corporation, Myriad Genetics Inc., Luminex Corporation, Gene By Gene Ltd., MedGenome Inc., Natera Inc., Laboratory Corporation of America Holdings, and Mount Sinai Genomics Inc. are among the most well-known companies in the global carrier screening market.

Comments

Popular posts from this blog

Continuous Glucose Monitoring (CGM) Devices Market -Dynamics and Forecast

YOU YES YOU!

Key Benefits of Breath Analyzer Market